Corrigendum to: "Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg" [Eur Urol 2007;52:1195-1203] (DOI:10.1016/j.eururo.2007.05.027);Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg

European Urology

Volumn 52, Issue 4, 2007, Pages 1195-1203

  Chapple, Christopher R ^a   Fianu Jonsson, Aino ^b   Indig, Mark ^c   Khullar, Vik ^d   Rosa, José ^e   Scarpa, Roberto M ^f   Mistry, Arun ^g   Wright, D Mark ^g   Bolodeoku, John ^g  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Dr Indig ^*  (Germany)

^d ST MARY S HOSPITAL   (United Kingdom)

^e Unidad de Enfermeria Urologica Hospital Santiago Apostol Miranda de Ebro Burgos Espana   (Spain)

^f SAN LUIGI GONZAGA HOSPITAL   (Italy)

^g ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

Author keywords

Antimuscarinic; Overactive bladder; Solifenacin; Tolterodine

Indexed keywords

PLACEBO; SOLIFENACIN; TOLTERODINE;

ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; NOCTURIA; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY URGENCY; XEROSTOMIA;

EID: 34548309193     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.04.036     Document Type: Erratum

References (19)

1. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thuroff J., and Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87 (2001) 760-766
2. Jackson S. The patient with overactive bladder - symptoms and quality-of-life issues. Urology 50 Suppl 6A (1997) 18-22
3. Odeyemi I., Dakin H.A., O'Donnell R.A., Warner J., Jacobs A., and Dasgupta P. Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. Int J Clin Pract 60 (2006) 949-958
4. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006:CD003781.
5. Haab F., Cardozo L., Chapple C., and Ridder A.M. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 47 (2005) 376-384
6. Abrams P., and Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol 48 (2005) 483-487
7. Chapple C.R. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55 Suppl 5A (2000) 33-46
8. Chapple C.R., Martinez-Garcia R., Selvaggi L., Toozs-Hobson P., Warnack W., Drogendijk T., et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48 (2005) 464-470
9. Chapple C.R., Rechberger T., Al-Shukri S., Meffan P., Everaert K., Huang M., et al. Randomised, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93 (2004) 303-310
10. Diokno A.C., Appell R.A., Sand P.K., Dmochowski R.R., Gburek B.M., Klimberg I.W., et al. Prospective, randomised, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA study. Mayo Clin Proc 78 (2003) 687-695
11. Kelleher C.J., Cardozo L.D., Khullar V., and Salvatore S. A medium-term analysis of the subjective efficacy of treatment of women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104 (1997) 988-993
12. Cisternas M., Noe L., Patel B., Remigio-Baker, Williamson T., and Black L. Comparison of persistence among therapies for overactive bladder: a retrospective pharmacy claims analysis. Neurourol Urodyn 24 (2005) 580
13. Staskin D.R., and MacDiarmid S.C. Pharmacologic management of overactive bladder: practical options for the primary care physician. Am J Med 119 3 Suppl 1 (2006) 245-285
14. Van Kerrebroeck P., Kreder K., Jonas U., Zinner N., and Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 57 (2001) 414-421
15. Fultz N.H., and Herzog R. Self reported and emotional impact of urinary incontinence. J Am Geriatr Soc 49 (2001) 892-899
16. Diokno A., Lee P., Zorn B.H., Lenderking W.R., Grossman M.A., Bull S.A., et al. Factors associated with clinical assessment of overactive bladder and selection of treatment. Clin Ther 23 (2001) 1542-1551
17. Wagner T.H., and Hu T.W. Economic cost of urinary incontinence in 1995. Urology 51 (1998) 355-361
18. Reeves P., Irwin D., Kelleher C., Milsom I., Kopp Z., Calvert N., and Lloyd A. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50 (2006) 1050-1057
19. Ricci J.A., Baggish J.S., Hunt T.L., Stewart W.F., Wein A., Herzog A.R., et al. Coping strategies and health care-seeking behaviour in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther 23 (2001) 1245-1259